donepezil

Donepezil (Aricept)

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">donepezil</th>
</tr>
<tr>
<td class="label">Parameter</td>
<td>Value</td>
</tr>
<tr>
<td class="label">Bioavailability</td>
<td>~100% (oral)</td>
</tr>
<tr>
<td class="label">Time to peak (Tmax)</td>
<td>3–4 hours</td>
</tr>
<tr>
<td class="label">Half-life</td>
<td>~70 hours</td>
</tr>
<tr>
<td class="label">Protein binding</td>
<td>~96% (albumin)</td>
</tr>
<tr>
<td class="label">Metabolism</td>
<td>CYP2D6, CYP3A4, glucuronidation</td>
</tr>
<tr>
<td class="label">Excretion</td>
<td>Renal (57%) and fecal (15%); unchanged drug ~17% in urine</td>
</tr>
<tr>
<td class="label">Steady state</td>
<td>~15 days</td>
</tr>
<tr>
<td class="label">Formulation</td>
<td>Dose</td>
</tr>
<tr>
<td class="label">Oral tablet</td>
<td>5 mg, 10 mg, 23 mg</td>
</tr>
<tr>
<td class="label">Orally disintegrating tablet</td>
<td>5 mg, 10 mg</td>
</tr>
<tr>
<td class="label">Transdermal patch</td>
<td>5 mg/day, 10 mg/day</td>
</tr>
<tr>
<td class="label">Feature</td>
<td>Donepezil</td>
</tr>
<tr>
<td class="label">AChE selectivity</td>
<td>AChE >> BuChE</td>
</tr>
<tr>
<td class="label">Mechanism</td>
<td>Non-competitive</td>
</tr>
<tr>
<td class="label">Half-life</td>
<td>~70 hours</td>
</tr>
<tr>
<td class="label">Dosing</td>
<td>Once daily</td>
</tr>
<tr>
<

...

Donepezil (Aricept)

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">donepezil</th>
</tr>
<tr>
<td class="label">Parameter</td>
<td>Value</td>
</tr>
<tr>
<td class="label">Bioavailability</td>
<td>~100% (oral)</td>
</tr>
<tr>
<td class="label">Time to peak (Tmax)</td>
<td>3–4 hours</td>
</tr>
<tr>
<td class="label">Half-life</td>
<td>~70 hours</td>
</tr>
<tr>
<td class="label">Protein binding</td>
<td>~96% (albumin)</td>
</tr>
<tr>
<td class="label">Metabolism</td>
<td>CYP2D6, CYP3A4, glucuronidation</td>
</tr>
<tr>
<td class="label">Excretion</td>
<td>Renal (57%) and fecal (15%); unchanged drug ~17% in urine</td>
</tr>
<tr>
<td class="label">Steady state</td>
<td>~15 days</td>
</tr>
<tr>
<td class="label">Formulation</td>
<td>Dose</td>
</tr>
<tr>
<td class="label">Oral tablet</td>
<td>5 mg, 10 mg, 23 mg</td>
</tr>
<tr>
<td class="label">Orally disintegrating tablet</td>
<td>5 mg, 10 mg</td>
</tr>
<tr>
<td class="label">Transdermal patch</td>
<td>5 mg/day, 10 mg/day</td>
</tr>
<tr>
<td class="label">Feature</td>
<td>Donepezil</td>
</tr>
<tr>
<td class="label">AChE selectivity</td>
<td>AChE >> BuChE</td>
</tr>
<tr>
<td class="label">Mechanism</td>
<td>Non-competitive</td>
</tr>
<tr>
<td class="label">Half-life</td>
<td>~70 hours</td>
</tr>
<tr>
<td class="label">Dosing</td>
<td>Once daily</td>
</tr>
<tr>
<td class="label">Indications</td>
<td>Mild-moderate-severe AD</td>
</tr>
<tr>
<td class="label">Unique features</td>
<td>Longest half-life, best tolerated</td>
</tr>
<tr>
<td class="label">Bioavailability</td>
<td>100%</td>
</tr>
<tr>
<td class="label">Half-life</td>
<td>70 hours</td>
</tr>
<tr>
<td class="label">Cmax</td>
<td>4-8 hours</td>
</tr>
<tr>
<td class="label">Protein binding</td>
<td>96%</td>
</tr>
<tr>
<td class="label">Metabolism</td>
<td>CYP2D6, CYP3A4</td>
</tr>
<tr>
<td class="label">Excretion</td>
<td>Renal</td>
</tr>
<tr>
<td class="label">Measure</td>
<td>Improvement</td>
</tr>
<tr>
<td class="label">ADAS-Cog</td>
<td>2-3 points</td>
</tr>
<tr>
<td class="label">MMSE</td>
<td>0.5-1 point</td>
</tr>
<tr>
<td class="label">ADL</td>
<td>Clinically meaningful</td>
</tr>
<tr>
<td class="label">Global</td>
<td>Stable for 12+ months</td>
</tr>
</table>

Introduction

Donepezil (Aricept) is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.

Overview

Donepezil (brand name Aricept) is a centrally-acting, reversible acetylcholinesterase (AChE) inhibitor and the most widely prescribed medication for Alzheimer's disease. Developed by Eisai and co-marketed with Pfizer, donepezil was first approved by the FDA in 1996 and provides symptomatic relief by increasing acetylcholine levels in [@birks2018]
the brain, compensating for the progressive loss of cholinergic neurons — particularly in the nucleus basalis of Meynert — that characterizes Alzheimer's pathology.[@rogers1998] [@noetzli2013]

Donepezil is approved for the treatment of mild, moderate, and severe [Alzheimer's Disease](/diseases/alzheimers-disease). While it does not modify the underlying disease process or halt neurodegeneration, it remains a first-line pharmacotherapy that can temporarily stabilize or modestly improve cognitive function, daily activities, and behavioral symptoms. It is one of three cholinesterase inhibitors approved for AD, alongside galantamine and rivastigmine.[@birks2018] Donepezil became available as a generic medication in November 2010 following patent expiration, and is now manufactured by numerous generic pharmaceutical companies worldwide. [@kim2017]

Mechanism of Action

Cholinergic Hypothesis

Donepezil's mechanism is rooted in the cholinergic hypothesis of [Alzheimer's Disease](/diseases/alzheimers-disease), which posits that degeneration of cholinergic neurons in the basal forebrain — particularly the [nucleus basalis of Meynert](/brain-regions/nucleus-basalis) — leads to a deficit of acetylcholine (ACh) in cortical and [hippocampal](/brain-regions/hippocampus) regions, contributing to the cognitive symptoms of AD. The cholinergic deficit correlates with disease severity: mild AD patients show approximately 50% reduction in cortical choline acetyltransferase (ChAT) activity, increasing to >90% reduction in severe disease. [@zhang2024]

AChE Inhibition

Donepezil binds reversibly and non-competitively to acetylcholinesterase (AChE), the enzyme responsible for hydrolyzing ACh in synaptic clefts. Key pharmacological properties: [@zhao2024]

• High AChE selectivity: Donepezil is approximately 1,000-fold more selective for AChE over butyrylcholinesterase (BuChE), distinguishing it from rivastigmine, which inhibits both enzymes. This selectivity is clinically significant because BuChE activity increases in AD brains while AChE decreases
• Central selectivity: Preferentially inhibits brain AChE over peripheral AChE, reducing gastrointestinal side effects compared to physostigmine and tacrine
• Long half-life: Elimination half-life of approximately 70 hours, enabling convenient once-daily dosing and maintaining stable plasma levels at steady state[@noetzli2013]
• Reversible binding: Binds to both the catalytic active site (CAS) and peripheral anionic site (PAS) of AChE, with particularly high affinity for the PAS — which is also the site where [amyloid-beta](/proteins/amyloid-beta) interacts with AChE, potentially conferring additional anti-amyloid properties
• AChE inhibition: At therapeutic doses, donepezil inhibits approximately 25–40% of brain AChE activity, as measured by PET studies using 11Cdonepezil

By inhibiting AChE, donepezil increases the concentration and duration of action of ACh at cholinergic synapses throughout the cerebral [cortex](/brain-regions/cortex) and [hippocampus](/brain-regions/hippocampus), supporting cholinergic neurotransmission that underlies attention, memory, and learning. [@farlow2010]

Potential Non-Cholinergic Effects

Emerging research suggests donepezil may have additional neuroprotective and disease-modifying effects beyond cholinergic enhancement: [@howard2012]

• Anti-inflammatory effects: Modulation of microglial[@kim2017]
• Anti-amyloid effects: Reduction of amyloid-beta production and aggregation in preclinical models, potentially through upregulation of the non-amyloidogenic α
• Anti-excitotoxic effects: Protection against [glutamate excitotoxicity](/mechanisms/excitotoxicity) via modulation of NMDA receptor activity
• Nicotinic receptor upregulation: Chronic donepezil treatment upregulates nicotinic acetylcholine receptors (nAChRs), particularly α4β2 and α7 subtypes, which are important for synaptic plasticity and neuroprotection[@kim2017]
• Cerebrovascular effects: Improvement of cerebral blood flow, potentially through nitric oxide-mediated vasodilation and reduced blood-brain barrier dysfunction

Effect on Hippocampal Atrophy

A 2024 systematic review and meta-analysis found that AChE inhibitors — particularly donepezil at 10 mg — significantly reduce the rate of [hippocampal atrophy](/brain-regions/hippocampus) in both [AD](/diseases/alzheimers-disease) and [mild cognitive impairment (MCI](/diseases/mild-cognitive-impairment)) patients compared to placebo. This structural preservation suggests a potential neuroprotective effect beyond purely symptomatic cholinergic enhancement, though the mechanism remains under investigation.[@zhang2024] [@park2024]

Clinical Efficacy

Mild to Moderate Alzheimer's Disease

In randomized controlled trials, donepezil at 5 mg and 10 mg daily demonstrated: [@cacabelos2007]

• ADAS-Cog improvement: 2.5–3.1 point improvement over placebo at 24 weeks (clinically meaningful threshold is typically 4 points)[@rogers1998]
• CIBIC-plus: Statistically significant improvement in global clinical impression
• MMSE: Modest improvement of 1.0–1.8 points over placebo at 24 weeks
• Activities of Daily Living (ADL): Significant preservation of functional abilities

A 2018 Cochrane meta-analysis encompassing 30 trials confirmed these findings, concluding that donepezil produces modest but consistent benefits on cognitive function, activities of daily living, and clinician-rated global clinical state in mild to moderate AD.[@birks2018] [@sugimoto1995]

A 2024 systematic review and meta-analysis comparing 5 mg and 10 mg doses found that donepezil 10 mg/day is more efficacious than 5 mg/day for improving cognitive function, supporting dose-dependent therapeutic effects.[@zhao2024] [@arai2018]

Severe Alzheimer's Disease

Donepezil 10 mg and 23 mg formulations have shown:

• Modest cognitive benefits on the Severe Impairment Battery (SIB)
• Functional improvement on the ADCS-ADL-severe scale
• The 23 mg dose provides greater cognitive benefit than 10 mg but with more gastrointestinal side effects[@farlow2010]

Duration of Benefit

• Benefits are typically observed within 3–6 months of initiation
• The symptomatic effect diminishes as the disease progresses and cholinergic neurons are further lost
• Discontinuation often leads to rapid decline to a level comparable to untreated patients
• Some patients show benefit for 2–3 years; the drug does not halt disease progression
• The DOMINO-AD trial showed that discontinuing donepezil in moderate-to-severe AD led to significantly worse cognitive and functional outcomes compared to continuation, supporting continued use even in later disease stages[@howard2012]

Real-World Evidence

Real-world studies have generally confirmed trial findings, with some caveats:

• Adherence rates decline over time, with only ~50–60% of patients continuing treatment at 1 year
• Common reasons for discontinuation include perceived lack of efficacy, gastrointestinal side effects, and caregiver burden
• Patients who respond well in the first 3 months are more likely to show sustained benefit
• Long-term observational studies suggest donepezil users may have slower rates of nursing home placement compared to non-users

Pharmacokinetics

The long half-life (70 hours) is a distinguishing feature of donepezil, permitting once-daily dosing and providing stable cholinesterase inhibition throughout the day. This contrasts with rivastigmine (half-life ~1.5 hours for oral, ~3 hours for patch) and galantamine (half-life ~7 hours), which require twice-daily or extended-release formulations.

Pharmacogenomics

Donepezil is primarily metabolized by CYP2D6 and CYP3A4 in the liver. Genetic polymorphisms in CYP2D6 affect drug metabolism:

• Poor metabolizers (PM): Show ~31.5% slower clearance and higher plasma levels
• Ultra-rapid metabolizers (UM): Show ~24% faster clearance and potentially subtherapeutic levels
• Extensive metabolizers (EM): Standard pharmacokinetic profile

A 2024 Korean study found that while donepezil plasma concentrations differed significantly among CYP2D6 metabolizer phenotypes, these differences did not significantly affect
3-year cognitive outcomes (MMSE) or adverse event rates, suggesting that routine CYP2D6 genotyping may not be necessary for donepezil dosing.[@park2024] However, other studies have
reported that specific genotypes (e.g., CYP2D6 G/G) are associated with higher response rates, and the clinical utility of pharmacogenomic testing remains an active area of
investigation.[@cacabelos2007]

Dosing and Administration

Titration: Start at 5 mg daily for at least 4–6 weeks before increasing to 10 mg. The 23 mg dose (for moderate-to-severe AD) should only be initiated after at least 3 months on 10 mg daily. Dose adjustments are not required for renal or hepatic impairment, though caution is advised in severe hepatic disease.

Administration: Donepezil can be taken with or without food. Bedtime administration is often preferred to minimize awareness of cholinergic side effects (vivid dreams, insomnia may require morning dosing).

Safety Profile

Common Adverse Effects

• Gastrointestinal: Nausea (11%), diarrhea (10%), vomiting (5%) — dose-related; more common at higher doses and during titration. GI effects are the most common reason for discontinuation
• Neurological: Insomnia (9%), dizziness (5%), abnormal dreams, headache
• Musculoskeletal: Muscle cramps (6%), particularly in the calves and feet
• Cardiovascular: Bradycardia, syncope (especially in patients on beta-blockers or with sick sinus syndrome)
• Other: Fatigue, anorexia, weight loss

Serious Adverse Effects

• Cardiac: QT prolongation, bradycardia, heart block (rare); the vagotonic effect of increased ACh can slow heart rate. ECG monitoring is recommended in patients with cardiac conduction abnormalities
• GI: Peptic ulcer disease exacerbation, GI bleeding (rare) — ACh stimulates gastric acid secretion
• Seizures: Very rare; ACh excess can lower seizure threshold
• Rhabdomyolysis: Very rare; reported in association with neuroleptic malignant syndrome
• Hepatotoxicity: Very rare; unlike its predecessor tacrine, donepezil has an excellent hepatic safety profile

Drug Interactions

• CYP2D6 and CYP3A4 inhibitors (ketoconazole, fluoxetine, paroxetine): May increase donepezil levels; monitor for cholinergic side effects
• CYP3A4 inducers (rifampin, phenytoin, carbamazepine): May decrease donepezil levels, potentially reducing efficacy
• Anticholinergic medications (oxybutynin, diphenhydramine, tricyclic antidepressants): Directly counteract donepezil's mechanism — concomitant use is a common and avoidable cause of treatment failure
• Succinylcholine-type muscle relaxants: Enhanced and prolonged effect due to AChE inhibition; important to communicate to anesthesiologists before surgery
• NSAIDs: Increased GI bleeding risk due to combined effects on gastric mucosa
• Beta-blockers and calcium channel blockers: Additive bradycardic effects

Combination Therapy

Donepezil + Memantine

The most common combination for moderate-to-severe AD. Memantine, an NMDA receptor receptor] antagonist, acts through a complementary mechanism by reducing glutamate-mediated excitotoxicity. The fixed-dose combination product Namzaric (donepezil 10 mg + memantine ER 28 mg) simplifies dosing. The DOMINO-AD trial showed that the combination provided additional benefit over either drug alone in moderate-to-severe AD.[@howard2012]

Donepezil + Anti-Amyloid Antibodies

With the FDA approval of lecanemab (2023) and donanemab (2024), a new treatment paradigm has emerged combining symptomatic therapy (donepezil) with disease-modifying anti-amyloid therapy. Patients in the pivotal trials of these antibodies typically continued cholinesterase inhibitors, and current clinical practice recommends maintaining donepezil alongside anti-amyloid therapy. The rationale is complementary: donepezil boosts residual cholinergic signaling while anti-amyloid antibodies reduce amyloid-beta plaque burden to slow disease progression.

Donepezil + Non-Pharmacological Interventions

Donepezil is most effective as part of a comprehensive AD management plan that includes:

• Cognitive stimulation therapy
• Physical exercise programs
• Caregiver education and support
• Management of cardiovascular risk factors
• Treatment of comorbid depression and sleep disorders

Comparison with Other Cholinesterase Inhibitors

Head-to-head comparisons generally show similar efficacy among the three agents, with differences primarily in tolerability and dosing convenience. Donepezil's once-daily dosing and long half-life make it the most commonly prescribed first-line agent.

Off-Label Uses

Donepezil has been investigated for several off-label indications, with varying levels of evidence:

• Vascular Dementia: Modest cognitive benefits in controlled trials
• Lewy body dementia: Some evidence for cognitive and behavioral improvement; may be better tolerated than antipsychotics
• Parkinson's disease dementia: Positive trial data, though rivastigmine is the approved agent
• Down syndrome-associated dementia: Limited evidence of benefit
• Traumatic brain injury: Investigated for cognitive rehabilitation
• Multiple sclerosis-related cognitive impairment: Inconsistent results

See Also

• [Memantine](/therapeutics/memantine)

External Links

• [Donepezil — StatPearls (NCBI Bookshelf)](https://www.ncbi.nlm.nih.gov/books/NBK513257/)
• [DrugBank — Donepezil](https://go.drugbank.com/drugs/DB00843)
• [FDA Label — Aricept](https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/020690s039,021720s015,022568s011lbl.pdf)

Background

The study of Donepezil (Aricept) has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.

Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.

Allen Brain Atlas Resources

• [Allen Brain Atlas - Gene Expression](https://human.brain-map.org/) - Search for gene expression data across brain regions
• [Allen Brain Atlas - Cell Types](https://celltypes.brain-map.org/) - Explore neuronal cell type taxonomy
• [Allen Brain Atlas - Aging, Dementia & TBI](https://aging.brain-map.org/) - Data on aging and traumatic brain injury

Cholinergic Enhancement Mechanism

Pharmacokinetic Properties

Clinical Efficacy

References

[Unknown, Rogers SL, Doody RS, Mohs RC, Friedhoff LT. Donepezil improves cognition and global function in Alzheimer's Disease: a 15-week, double-blind, placebo-controlled study. Arch Intern Med. 1998;158(9):1021-1031. . [DOI (1998)](https://doi.org/10.1001/archinte.158.9.1021)

[Unknown, Birks JS, Harvey RJ. Donepezil for dementia due to Alzheimer's Disease. Cochrane Database Syst Rev. 2018;6(6):CD001190. . [DOI (2018)](https://doi.org/10.1002/14651858.CD001190.pub3)

[Unknown, Noetzli M, Eap CB. Pharmacodynamic, pharmacokinetic and pharmacogenetic aspects of drugs used in the treatment of Alzheimer's Disease. Clin Pharmacokinet. 2013;52(4):225-241. . [DOI (2013)](https://doi.org/10.1007/s40262-013-0038-9)

[Kim SH, Kandiah N, Hsu JL, et al., Beyond symptomatic effects: potential of donepezil as a neuroprotective agent and disease modifier in Alzheimer's Disease. Br J Pharmacol. 2017;174(23):4224-4232. . [DOI (2017)](https://doi.org/10.1111/bph.14030)

[Zhang J, et al., Efficacy of acetylcholinesterase inhibitors on reducing hippocampal atrophy rate: a systematic review and meta-analysis. BMC Neurol. 2024;24:440. . [DOI (2024)](https://doi.org/10.1186/s12883-024-03933-4)

[Zhao L, et al., Efficacy of 5 and 10 mg donepezil in improving cognitive function in patients with dementia: a systematic review and meta-analysis. Front Neurosci. 2024;18:1398952. . [DOI (2024)](https://doi.org/10.3389/fnins.2024.1398952)

[Farlow MR, Salloway S, Tariot PN, et al, Effectiveness and tolerability of high-dose (23 mg/d] versus standard-dose (10 mg/d) donepezil in moderate to severe Alzheimer's Disease (2010)]([DOI:10.1016/j.clinthera.2010.06.019)(https://doi.org/10.1016/j.clinthera.2010.06.019))

[Howard R, McShane R, Lindesay J, et al., Donepezil and memantine for moderate-to-severe Alzheimer's Disease. N Engl J Med. 2012;366(10):893-903. . [DOI (2012)](https://doi.org/10.1056/NEJMoa1106668)

[Park SH, et al., The impact of CYP2D6 on donepezil concentration and its lack of effect on the treatment response and adverse effect in Korean patients with Alzheimer's Disease. Pharmacogenomics J. 2024. [PubMed (2024)](https://pubmed.ncbi.nlm.nih.gov/39539179/)

Unknown, Cacabelos R. Donepezil in Alzheimer's Disease: from conventional trials to pharmacogenetics. Neuropsychiatr Dis Treat. 2007;3(3):303-333. [PMC (2007)

[Sugimoto H, Iimura Y, Yamanishi Y, Yamatsu K, Synthesis and structure-activity relationships of acetylcholinesterase inhibitors: 1-benzyl-4-[(5,6-dimethoxy-1-oxoindan-2-yl]methyl]piperidine hydrochloride and related compounds (1995)]([DOI:10.1021/jm00024a009)(https://doi.org/10.1021/jm00024a009))

[Arai H, Hashimoto N, Sumitomo K, et al, Disease state changes and safety of long-term donepezil hydrochloride administration in patients with Alzheimer's Disease (2018))

Related Hypotheses

From the [SciDEX Exchange](/exchange) — scored by multi-agent debate

• [Microbial Inflammasome Priming Prevention](/hypothesis/h-e7e1f943) — <span style="color:#81c784;font-weight:600">0.76</span> · Target: NLRP3, CASP1, IL1B, PYCARD
• [Selective APOE4 Degradation via Proteolysis Targeting Chimeras (PROTACs)](/hypothesis/h-11795af0) — <span style="color:#ffd54f;font-weight:600">0.56</span> · Target: APOE

Related Analyses:

• [APOE4 structural biology and therapeutic targeting strategies](/analysis/SDA-2026-04-01-gap-010) &#x1f504;
• [What are the mechanisms by which gut microbiome dysbiosis influences Parkinson&#x27;s disease pathogenesi](/analysis/SDA-2026-04-01-gap-20260401-225155) &#x1f504;